 | Up a level |
Dreger, P., Michallet, M., Bosman, P., Sobh, M., Boumendil, A., Nagler, A., Scheid, C., Cornelissen, J., Mueller, L., Niederwieser, D., Vandenberghe, E., Scortechini, I., Schoemans, H., Andersen, N., Finke, J., Russo, D., Ljungman, P., Passweg, J., van Gelder, M., Durakovic, N., Labussiere, H., Berg, T., Wulf, G., Bethge, W., Stilgenbauer, S., Mordini, N., Schaap, M., Fox, C., Kroeger, N., Montoto, S. and Schetelig, J. (2017). Ibrutinib for bridging to allogeneic hematopoietic stem cell transplantation (alloHCT) in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) is safe and effective: Updated results of a study by the EBMT Chronic Malignancy and Lymphoma Working Parties, the French Cooperative Group for CLL, and the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC). Bone Marrow Transplant., 52. S. S99 - 1. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365
Malard, F., Labopin, M., Stuhler, G., Bittenbring, J., Ganser, A., Tischer, J., Michallet, M., Kroeger, N., Schmid, C., Huynh, A., Hallek, M., Savani, B., Mohty, M. and Nagler, A. (2016). Sequential intensified conditioning regimen allogeneic hematopoietic stem cell transplantation in adult patients with high-risk AML in complete remission: a survey from the ALWP of the EBMT. Bone Marrow Transplant., 51. S. S11 - 1. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365